PARP抑制剂在乳腺癌应用中的现状及前景  

Current Status and Prospects of PARP Inhibitorsin Breast Cancer Applications

作　　者：蓝天琪 韦京辰[1] Lan Tianqi;Wei Jingchen*(School of Pharmacy,Guilin Medical College,Guilin 541000,China)

机构地区：[1]桂林医学院药学院,广西桂林541000

出　　处：《山东化工》2024年第12期89-91,共3页Shandong Chemical Industry

摘　　要：PARP抑制剂可通过合成致死、PARP-DNA捕获等机制对恶性肿瘤产生抑制效果,在治疗包括乳腺癌在内的多种恶性肿瘤患者中取得巨大进展。通过对BRCA基因与乳腺癌、PARP抑制剂抗肿瘤分子机制及其在乳腺癌应用中的情况作一简单综述,以期提高人们对PARP抑制剂的认识,并且为未来临床应用提供参考。PARP inhibitors can produce inhibitory effects on malignant tumors through mechanisms such as synthetic lethality and PARP-DNA capture,and have made great progress in the treatment of patients with a variety of malignant tumors,including breast cancer.In this paper,we briefly review the BRCA gene and breast cancer,the anti-tumor molecular mechanism of PARP inhibitors and their application in breast cancer,with a view to improving the understanding of PARP inhibitors and providing references for future clinical applications.

关 键 词：乳腺癌 PARP抑制剂 分子靶向治疗 

分 类 号：TQ460[化学工程—制药化工]